Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

by Peter Johnson, Wolfgang Greiner, Imad Al-Dakkak, Samuel Wagner
Published 2015-01-01

Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry

by Eric Rondeau, Spero R. Cataland, Imad Al-Dakkak, Benjamin Miller, Nicholas J.A. Webb, Daniel Landau, MD
Published 2019-11-01

Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome

by Anne-Laure Lapeyraque, Martin Bitzan, Imad Al-Dakkak, Mira Francis, Shih-Han S. Huang, Roger Kaprielian, Loree Larratt, Katerina Pavenski, Christine Ribic, Axel Tosikyan, Christoph Licht, David Philibert
Published 2020-01-01